Advertisement

Topics

Astrazeneca Gets Another Boost With FDA Approval of Severe Asthma Drug

19:00 EST 14 Nov 2017 | BioSpace

The drug, in combination with abemaciclib, showed 16.4 Months of progression-free survival.

Original Article: Astrazeneca Gets Another Boost With FDA Approval of Severe Asthma Drug

NEXT ARTICLE

More From BioPortfolio on "Astrazeneca Gets Another Boost With FDA Approval of Severe Asthma Drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...